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Since 2004 kohnodai hospital has downsized psychiatric 
beds and introduced ICM (Intensive Care management ) 
for community care and developed the community care 
system among medical services and warfare agencies in 
Ichikawa city. It could make many patients who had 
long-term hospitalization or were frequent users of psy-
chiatric emergency to achieve safe and stable life in the 
community. 
The aim was to compare the effency of ICM service with 
standard community services for the patients with 
SMI(severe mentally ill). 
The patients who were with SMI and hospitalized in 
Kohnodai hospital from November 1 2011 to August 31 
2012 were divided two groups, those who were living in 
Ichikawa and living in elsewhere and compared outcome 
about readmission to psychiatric ward, drop out from 
community service and improvement of social function at 
12 months. 
We will provide the result in the presentation and more-
over refer to the effect of the care management system. 
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Practice based evidence: What determines clozap-
ine prescribing practice? 
 
Pai,N. B, Vella,SC 
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Wollongong, Australia 
 
The pharmacologic treatment of schizophrenia is charac-
terized by excessive use of antipsychotic polypharmacy, 
which reflects a gap between evidence and practice. 
Clozapine is underutilized and many psychiatrists tend to 
avoid clozapine and instead use non-evidence based 
treatments. It was advocated that clozapine could be util-
ised as long as strict protocols for its use were adhered 
too, namely the routine medical assessment of patients on 
clozapine therapy. This paper discusses the current evi-
dence relating to the underuse of clozapine and factors 
responsible for this. The aim of this paper is to present 
and to discuss the practice of therapeutic patterns in re-
fractory schizophrenia. 
Would it be preferable to define a continuum of treatment 
responsiveness rather than a small population of treat-
ment-resistant patients? Do clozapine clinics address the 
reasons behind lack of compliance to recommended prac-
tice of clozapine? Sustained response rates, relapse and 
hospitalization rates, and effects on symptoms and func-
tioning are debated in this paper. 
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